{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-046067","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.714896+00:00","generated_at":"2026-05-24T03:50:28.910085+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kodiak Sciences reports Q4 net loss of $44.1M, cash $168.1M; pipeline trials on track","bullets":["Cash and equivalents $168.1M at Dec 31, 2024; expected to fund operations into 2026.","Q4 2024 net loss $44.1M ($0.84/sh) vs $59.5M ($1.13/sh) in Q4 2023; R&D expenses $31.8M.","Tarcocimab Phase 3 GLOW2 (diabetic retinopathy) enrollment complete; topline data targeted 1Q2026.","Tarcocimab & KSI-501 Phase 3 DAYBREAK (wet AMD) enrollment complete; topline data targeted 2Q2026.","KSI-101 granted FDA Orphan Drug Designation; pivotal study initiation expected 2Q2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-046067","json":"https://secwatch.observer/filing/0000950170-25-046067.json","markdown":"https://secwatch.observer/filing/0000950170-25-046067.md","text":"https://secwatch.observer/filing/0000950170-25-046067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017025046067/0000950170-25-046067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017025046067/kod-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:50:28.910085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}